Jay Barth, M.D.

Dr. Barth brings to eGenesis over 25 years of industry experience within the biotech and pharmaceutical sectors leading clinical development of transformational therapies.

His industry experience spans multinational pharmaceutical companies as well as private and public biotechnology companies. Dr. Barth most recently served as Chief Medical Officer at Ascidian Therapeutics, where he helped build the Clinical team and advance the company’s novel RNA Exon Editing technology into the clinic. Prior to this, he served as Chief Medical Officer at Lexeo Therapeutics, joining the company prior to the closing of its Series A round and helping to build a Clinical and Regulatory organization to support advancement of cutting-edge gene therapy research. Before his role at Lexeo, Dr. Barth was CMO of Amicus Therapeutics, where he was a member of the Executive Committee and significantly scaled the Development organization in support of advancing therapies for rare and orphan diseases, advancing multiple programs from Phase I through Phase IV. Prior to joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc., including Senior Vice President, Clinical Development. Earlier, Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc.

Dr. Barth earned his B.A. from Columbia University and M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Society of Human Genetics and American Society of Gene & Cell Therapy. Dr. Barth has featured authorship in numerous publications in the fields of medicine and clinical research.